German researchers recently published a study indicating that the presence of eczema in early childhood can lead to the development of allergies in the future. Also known as atopic dermatitis or atopic eczema, the skin condition affects up to 20% of children, or roughly 9.6 million children under 18 in the United States.
Children are more likely to develop eczema than adults, and around one-third of them will experience moderate to severe symptoms of eczema once the condition manifests. Research findings published in the “Nutrients” journal examined the potential long-term effects of developing eczema in the first three years of childhood, especially in regard to future allergies. The study also investigated whether the presence of eczema in early childhood could alter the relationship between allergies and breastfeeding.
Estimates from the American College of Allergy, Asthma and Immunology show that about 50 million Americans suffer from allergies each year, with conditions such as allergic rhinitis, eczema and food allergies being among the most reported conditions. Allergies cost the U.S. more than $20 billion per year in healthcare, and they are the sixth largest cause of chronic illness in America.
In the recent German study, researchers wanted to see if eczema in early life could affect the development of allergic infections into young adulthood. The researchers analyzed data collected from 4,058 participants of the GINIplus study from birth until they were 20 years old, focusing on physician-reported instances of atopic eczema, asthma and rhinitis.
The presence of eczema in early life was primarily reported by parents in questionnaires while breastfeeding data (to determine any changes in the association between atopic diseases and breastfeeding) came from regularly updated diaries. The research team also used data collected from 5,991 infants in urban and rural Germany from 1995 to 1998, excluding mothers suffering from autoimmune and chronic diseases such as diabetes.
Children who had a history of allergies in their families had a higher risk of developing eczema in early life compared to children with no family history of allergies. Furthermore, the researchers found an association between early-life eczema and later development of allergic rhinitis and asthma that steadily reduced as the children got older.
Infants diagnosed with early eczema were much more likely to develop asthma and allergic rhinitis compared to infants without the condition.
The study also revealed a “non-significant” relationship between breastfeeding and the development of allergic conditions from 5 to 20 years of age. Early eczema also had minimal effects on the association between allergy development and breastfeeding.
Eczema has become such a big concern that companies such as Jupiter Wellness Inc. (NASDAQ: JUPW) have invested significant resources in developing treatments to help those affected to manage their symptoms and enjoy a better quality of life.
NOTE TO INVESTORS: The latest news and updates relating to Jupiter Wellness Inc. (NASDAQ: JUPW) are available in the company’s newsroom at https://ibn.fm/JUPW
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
